Implant shows 75% pain relief in refractory angina, highlighting near-term medical device investment opportunities
Executive summary: A study published in August 2026 found that an implantable device reduced chest pain in 75% of patients suffering from refractory angina. The device offers a new therapeutic option for a patient group with limited treatments, potentially creating a new market segment for implantable cardiology technologies.
Who is involved: Researchers behind the study (unspecified in excerpt), the device manufacturer (not named), and the NHS as the prospective payer.
Likely next: Further clinical trials are planned and the manufacturer will seek NHS approval, a process that could take several months to over a year.
The Guardian reports that a recent study found an implantable device cut chest pain in 75% of patients with refractory angina, offering meaningful symptom relief where drugs fail. While the results are promising, the technology still requires additional trials and must secure NHS approval before it can be routinely used. This underscores the typical pathway for novel cardiac devices, where early efficacy data must be weighed against regulatory and reimbursement hurdles.
Timeline
- — Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy (PR Newswire)
- — New daily diabetes pill that helps with weight loss launches in UK pharmacies (The Guardian — Science)
- — ‘An amazing relief’: implant offers hope for those with refractory angina (The Guardian — Science)
Analysis — what this means
Sectors affected
- Cardiology medical devices
- Interventional cardiology
- NHS medical technology procurement
Historical parallels
- FDA approval of MitraClip for mitral regurgitation (2013)
- NHS adoption of transcatheter aortic valve replacement (TAVR) (2007)
Sources
- ‘An amazing relief’: implant offers hope for those with refractory angina — The Guardian — Science
- New daily diabetes pill that helps with weight loss launches in UK pharmacies — The Guardian — Science
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy — PR Newswire
Related cases
- NICE recommends systematic NHS funding for Bridge to Life's VitaSmart hypothermic oxygenated perfusion system
- NHS pension administration error leaves retiree declared deceased and without payments
- Decade-long UK study reveals men with heart disease face significantly higher cancer incidence and mortality, highlighting gender-specific health risks with implications for healthcare costs and insurance
- London startup to trial drug preventing cytokine storm in cancer patients